Image Credit: Canva
A condition, known commonly as "black urine disease" or Alkaptonuria is a rare genetic disorder involving protein metabolism, and it has its root in the mutation of the homogentisate 1,2-dioxygenase gene, which in turn causes homogentisic acid accumulation in the body. The appearance of dark urine after exposure to air is due to this kind of accumulation; however, a variety of symptoms can be expected, such as joint stiffness, changes in pigmentation, and other long-term health complications. Although the prevalence has been estimated to be between 1 in 250,000 and 1 in 1 million people in the United States, its effects are indeed high on those affected.
Alkaptonuria is an autosomal recessive disease, meaning that the child must inherit a defective copy of the HGD gene from both parents. If both parents are carriers, their offspring have a 25% chance of inheriting two faulty genes and developing alkaptonuria. The condition is genetic but is often not diagnosed for years because it progresses slowly and its early symptoms appear to be harmless.
The most characteristic and common initial symptom of alkaptonuria is dark urine. The reason for this is due to the fact that excess HGA is excreted in the urine and upon oxidation in the presence of air, it gives the urine a brown or black color. Though it is often considered cosmetic, the long-term accumulation of HGA within the connective tissues produces more complicated health problems.
Progressive joint pain and stiffness: The accumulation of HGA in cartilage leads to early-onset osteoarthritis, making movement increasingly difficult over time.
Skin and eye pigmentation changes: Affected individuals may develop bluish or grayish discoloration of the sclera (white part of the eye) and the skin, particularly in areas exposed to friction.
Cardiovascular and respiratory problems: With age, HGA accumulation can lead to valve calcifications in the heart and stiffening of connective tissues in the respiratory tract, which can cause problems in middle and old age.
Decreased mobility and spinal problems: The spine may become stiff and painful due to chronic cartilage degeneration.
These symptoms usually begin to manifest during adulthood, leading to severe complications in a person's 40s or 50s and significantly affecting the quality of their life.
Because of its rarity, alkaptonuria is often mistaken or overlooked early in life. However, there are several ways to confirm the condition:
Urine Testing: The gold standard in the diagnosis is the testing of urine samples for high levels of homogentisic acid via gas chromatography. In case of oxidation, which changes the color of urine to black, it is indicative of alkaptonuria.
Genetic Testing: Confirmatory genetic testing reveals mutations of the HGD gene to diagnose the condition conclusively.
Blood Tests: High levels of HGA in the blood can be used as further evidence.
Imaging Studies: X-rays and MRIs will expose cartilage and joint damage characteristic of alkaptonuria.
At present, there is no cure for alkaptonuria; however, various treatment approaches can reduce its symptoms and slow the disease's progress:
Nitisinone Therapy: Nitisinone is a drug that inhibits the production of HGA. It has been shown to reduce HGA levels and slow tissue damage. However, it needs to be taken under close medical supervision because of potential side effects.
Low-Protein Diet: Since HGA is a byproduct of protein metabolism, reducing protein intake—especially foods rich in tyrosine and phenylalanine—may help decrease HGA production.
Pain Management: OTC pain relievers and anti-inflammatory medications can be used to relieve joint pain and stiffness.
Physical Therapy: Exercise regularly, as it may improve mobility and strengthen muscles, thus reducing strain on affected joints.
Surgical Interventions: Most people with alkaptonuria develop severe osteoarthritis necessitating joint replacement in their old age. Also, some may require heart valve replacement surgery if cardiovascular complications develop.
Although alkaptonuria is not fatal, it severely affects the quality of life. The progressive deterioration of the joints and associated symptoms can make everyday activities difficult, requiring lifestyle changes and medical interventions. The disease may cause premature aging of the joints, requiring walking aids and mobility assistance earlier than expected.
Ongoing research will continue to work on improving the treatment options by focusing on gene therapy and alternative enzyme replacement therapies. However, because of its rarity, the clinical trials and research remain sparse.
As genetic research advances, more hope for better management and possible curative approaches for alkaptonuria exists. Scientists are searching extensively for enzyme replacement therapies and innovative drugs that can target the root cause of the disorder. Being aware and being diagnosed early helps individuals better their condition and ultimately have better long-term health outcomes.
Alkaptonuria is a striking example of how one gene mutation can have widespread effects on the body. Though still a rare and often misunderstood condition, growing awareness and advances in treatment are paving the way for better care. If you or a loved one suspect symptoms of alkaptonuria, it is essential to seek early diagnosis and medical guidance to manage the disease effectively and preserve quality of life.
Credits: GoFundMe
For most parents, the toddler years are filled with first words, wobbly steps and dreams of the future. For Gus and Emily Forrester, those moments are now overshadowed by a diagnosis they describe as “every parent’s worst nightmare.”
Their two-year-old daughter, Leni, has been diagnosed with Sanfilippo Syndrome Type B, a rare genetic condition often referred to as childhood dementia. The disorder, formally known as Mucopolysaccharidosis type III, gradually robs children of their physical and cognitive abilities.
In an interview with ITV News, Leni’s parents spoke about the devastating reality of the condition, which has no approved cure or widely available treatment.
“All your dreams for your child's future are taken away,” her mother, Emily, said. “To be told that she has this condition, and there is no treatment and no cure and no support… it’s completely earth-shattering.”

Sanfilippo Syndrome is a neurodegenerative disorder caused by the body’s inability to break down certain complex sugars. Over time, these substances build up in the brain, leading to progressive damage.
According to Cure Sanfilippo Foundation, symptoms usually begin appearing between the ages of one and six. Children may initially show mild developmental delays, but the disease gradually worsens, affecting speech, mobility and behaviour.
As the condition advances, many children lose the ability to talk, walk and recognise loved ones. Life expectancy is often limited to the early teenage years.
Emily explained the process in stark terms. Without treatment, she said, Leni’s body will slowly be overwhelmed by “toxic waste,” causing irreversible damage.
For families like the Forresters, time is not just precious, it is critical.
“Early treatment is key for these children,” Emily said. “If she has to wait six months, that could mean she can no longer talk. If she waits 12 months, that could mean she loses the ability to walk.”
Although experimental therapies, including gene-based approaches, are being developed, access remains a major hurdle. Some clinical trials are expected to take place in the United States later this year, but Leni is not currently eligible.
Her parents are now campaigning for UK patients to be included in these trials, arguing that promising science already exists but remains out of reach for many families.
In response to the diagnosis, the Forresters have launched a fundraiser to support Leni’s care and potential treatment options. They have also pledged to donate part of the funds to Great Ormond Street Hospital, where Leni is receiving care, and to the Cure Sanfilippo Foundation, which supports affected families.
So far, donations have crossed $250,000, reflecting the growing awareness and concern around rare childhood conditions.
Leni’s father, Gus, said the emotional toll of the diagnosis is hard to put into words. “As parents, your role is to protect your children and provide every opportunity you can. Without any treatment, her future and her reality is very, very dark.”
Beyond fundraising, the couple is also raising awareness about childhood dementia and advocating for newborn screening programmes that could help detect such conditions earlier.
Experts working on experimental therapies say greater government investment is urgently needed. Without it, many children may never benefit from treatments that could slow or alter the course of the disease.
For now, Leni remains a cheerful two-year-old, full of life and affection. But for her parents, every passing day is a reminder of how quickly that could change, and how urgently answers are needed.
Every year, March 24 is observed as World Tuberculosis Day to spread awareness about the infectious disease. In India, it remains one of the most pressing infectious diseases. Dr Arup Halder, Consultant Pomologist at CK Birla Hospitals, CMRI says that India still accounts for roughly a quarter to over a quarter of world's tuberculosis or TB cases. "In 2023–2024, India reported around 25–26 lakh TB patients out of an estimated 27 lakh cases, reflecting improved detection but also highlighting a persistently high burden," he points out.
Also Read: Harish Rana Taken Off Food And Water Support For Over 10 Days; Waiting For Passive Euthanasia
While TB incidence has fallen by about 20 per cent since 2015 and mortality has also declined to roughly 21 deaths per lakh population, it still remains well above national elimination targets for 2025.
What makes TB so difficult to eliminate? While many associate TB with persistent coughing, studies show that 80 per cent of patients do not show the symptoms of cough that is "presumed" to be a common symptom. This is why, TB could go ignored until it is too late.
A research led by Amsterdam UMC and the Amsterdam Institute for Global Health and Development analyzed data on more than 600,000 individuals in Africa and Asia and found that around 82.8 per cent of those with TB had no persistent cough. The study also found that 62.5 per cent had no cough at all. The findings were published in the Lancet Infectious Diseases.
Also Read: Perez Hilton Spent 21 Days In Hospital After Taking Medication on an Empty Stomach
The study in fact noted that this could be the "probable reason why, despite huge efforts to diagnose and treat the disease, the tb burden across Africa and Asia is hardly declining". Frank Cobelens, Professor of Global Health at Amsterdam UMC and Senior Fellow at the AIGHD says, "A persistent cough is often the entry point for a diagnosis, but if 80 per cent of those with TB do not have one, then it means that a diagnosis will happen later, possibly after the infection has already been transmitted to many others, or not at all."
Another 2019 study published in Elsevier notes: "Coughing does not appear to be a necessary prerequisite for TB transmission." The study further mentions, "Frequency of cough is associated with infectivity but this does not imply mechanistic causality for TB transmission."
The simple answer to this is: No. Coughing does not mean harmless, especially when it is a persistent one. The study only shows that TB does not always mean persistent coughing, however, if one experiences this symptom, they should always get a test done and should not ignore the symptoms.
Researchers from The University of Texas at Dallas' Center for Advanced Pain Studies working with colleagues from UT Southwestern Medical Center note that TB coughing could cause pain. This is one of the way one can distinguish the symptoms. The findings published in journal Cell notes that before this study, "no one had even shown that TB produces an irritant that acts directly on the sensory innervation of the lungs".
Corresponding author Dr Michael Shiloh, associate professor of internal medicine and microbiology at UT Southwestern said, "People with active tuberculosis can cough for months and spread disease even when they are receiving appropriate treatment."
Read: World Tuberculosis Day 2026: Theme, Origin, And Significance
On World TB Day, President Droupadi Murmu stressed that TB continues to pose a significant public health challenge and has affected millions of lives across the world. She urged all stakeholders to work together with collective resolve to end TB once for all.
To act on it, Union Health Minister Jagat Prakash Nadda will launch a series of initiatives, including 'TB Mukt Bharat Abhiyaan - 100 Days Campaign', the TB Mukt Bharat App, and the TB Mukt Urban Ward Initiative. These measures are designed to strengthen the case detection, improve treatment adherence, and enhance last-mile delivery of TB services, especially in high-burden areas. The initiatives have also been aligned with the objectives of the National Tuberculosis Elimination Programme.
Credit: Canva
From physical problems like fatigue and vision problems, people who survive the deadly bacterial meningitis are likely to live with long-term fatigue and vision problems, as well as be at high risk of suicide, according to a new study.
The study comes as the UK is experiencing an outbreak of meningitis in Kent, that began among students who visited Club Chemistry in Canterbury between March 5 and 7.
Although bacterial meningitis is treatable, it requires prompt, often immediate treatment for better recovery. Yet patients are likely to face the risk of fatal or long-term complications -- from physical, psychological, and social impacts, said researchers from the University of Otago, The Conversation reported.
The new findings, based on 16 cases from New Zealand, who reportedly suffered the fatal disease, showed that multiple chronic after-effects is permanent in some, while in others, it dragged on for years. The effects include:
"Our findings demonstrate that bacterial meningitis is much more than a life-threatening infection. It is an acute disease with serious, chronic after-effects which are poorly understood and often go unrecognised," the researchers said.
The bug that causes the infection has been identified as the known strain of meningitis B, and MenB vaccines will be offered to 5,000 students living in the University of Kent halls of residence in Canterbury.
Meanwhile, the UKHSA chief executive, Susan Hopkins, said the outbreak "looks like a super-spreader" event with "ongoing spread" through universities' halls of residence.
"There will have been some parties, particularly around this, so there will have been lots of social mixing. I can't yet say where the initial infection came from, how it's got into this cohort, and why it's created such an explosive amount of infections," she added.
As per Trish Mannes, UKHSA Regional Deputy Director for the South East, even after two doses, the MenB vaccine “does not protect against all strains of meningococcal disease, nor against all infections that can cause meningitis. It also does not prevent the bacteria from being carried and spread in the community”.
The UKHSA thus warned people to be aware of the signs and symptoms of invasive meningococcal disease, and to seek immediate medical attention if they or anyone they know develops these signs and symptoms.
Common symptoms include:
© 2024 Bennett, Coleman & Company Limited